Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 7Thoracic 4Gastrointestinal 4Gynecologic 3Genitourinary 2Dermatologic 2CNS 2Tumor-Agnostic 1Other hematologic neoplasm 1Other 1Head & Neck 1

Conditions

Uveal Melanoma 1Triple Negative Breast Neoplasms 1Neoplasms 1Melanoma 1Health Behavior 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Focus Groups × Dermatologic × Clear all
NCT04118062 2025-09-19

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Institut Curie

Phase NA Completed
128 enrolled
BreastDermatologic

Uveal Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT00518050 2015-07-16

Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns

Memorial Sloan Kettering Cancer Center

Completed
160 enrolled
Dermatologic

Melanoma, Health Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡